Sabeen Mekan - 01 Feb 2026 Form 3 Insider Report for Zymeworks Inc. (ZYME)

Role: SVP & Chief Medical Officer
Signature: /s/ Catherine Graham, Attorney-in-Fact
Issuer symbol: ZYME
Transactions as of: 01 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 02 Feb 2026, 20:37:00 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mekan Sabeen	SVP & Chief Medical Officer	C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN	/s/ Catherine Graham, Attorney-in-Fact	02 Feb 2026	0002106866

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ZYME	No securities are beneficially owned						0	01 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ZYME	Stock Option (Right to Buy)							01 Feb 2026	Common Stock	192,000	$11.75	Direct	F1, F2
holding	ZYME	Stock Option (Right to Buy)							01 Feb 2026	Common Stock	29,000	$23.16	Direct	F2, F3
holding	ZYME	Restricted Stock Unit							01 Feb 2026	Common Stock	19,000		Direct	F4, F5
holding	ZYME	Performance Stock Unit							01 Feb 2026	Common Stock	32,000		Direct	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock option granted April 21, 2025.
F2	Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F3	Stock option granted January 12, 2026.
F4	Restricted stock units ("RSUs") granted January 12, 2026. RSUs vest in four equal annual installments beginning on first anniversary of grant date.
F5	Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F6	Performance restricted stock units ("PSUs") granted January 12, 2026. Each PSU represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 16,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
F7	(Continued from footnote 6) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney